Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Gemcitabine, docetaxel, CPT-11 and cisplatin are effective in 1st line treatment of advanced
non-small cell lung cancer (NSCLC). Platinum-based doublets including gemcitabine, docetaxel
or CPT-11 are standard 1st regimens. BRCA1 and RRM1 expression levels are reported to be
associated with sensitivity of the tumor cells to cytotoxic agents. Some Phase II or III
trials did prove feasibility of customized chemotherapy based upon expression levels of one
or two biomarkers in the NSCLC patients. The investigators think customized chemotherapy may
further improve efficacy of chemotherapy in advanced NSCLC. But there is no randomised trial
to compare efficacy of standard chemotherapy with individualized chemotherapy in this
setting. So, the investigators plan to initiate this phase II trial to compare efficacy
between standard chemotherapy of gemcitabine/cisplatin versus customized chemotherapy in
chemonaive NSCLC patients.